Brief: Island Pharmaceuticals Got Feedback Following U.S. FDA Review Of Ind Application
20/01/2023 01:07
Jan 20 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* GOT FEEDBACK FOLLOWING U.S. FDA REVIEW OF IND APPLICATION
SUBMITTED FOR ISLA-101 PHASE 2A PEACH 1 CLINICAL TRIAL
* WILL WORK CLOSELY WITH FDA TO RESOLVE ISSUES AS QUICKLY AS
POSSIBLE
Source text for Eikon: ID:nASX3pczSy
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic